HC Wainwright Brokers Lift Earnings Estimates for COLL

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) - HC Wainwright boosted their Q3 2025 earnings estimates for shares of Collegium Pharmaceutical in a report released on Monday, March 24th. HC Wainwright analyst O. Livnat now expects that the specialty pharmaceutical company will earn $1.75 per share for the quarter, up from their prior estimate of $1.61. HC Wainwright currently has a "Buy" rating and a $50.00 target price on the stock. The consensus estimate for Collegium Pharmaceutical's current full-year earnings is $5.62 per share. HC Wainwright also issued estimates for Collegium Pharmaceutical's Q4 2025 earnings at $1.82 EPS, FY2025 earnings at $6.26 EPS and FY2026 earnings at $6.36 EPS.

A number of other equities research analysts have also issued reports on the stock. Needham & Company LLC raised shares of Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price target on the stock in a report on Friday, January 10th. Piper Sandler cut their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 4th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $43.60.

Collegium Pharmaceutical Trading Down 0.1 %

Shares of Collegium Pharmaceutical stock traded down $0.04 on Thursday, hitting $29.67. The stock had a trading volume of 40,225 shares, compared to its average volume of 436,716. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical has a one year low of $27.28 and a one year high of $42.29. The stock's 50-day simple moving average is $30.36 and its two-hundred day simple moving average is $32.40. The stock has a market cap of $934.19 million, a price-to-earnings ratio of 12.80 and a beta of 0.99.

Remove Ads

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The firm had revenue of $181.95 million for the quarter, compared to the consensus estimate of $179.68 million.

Insider Activity

In related news, EVP Shirley R. Kuhlmann sold 27,500 shares of Collegium Pharmaceutical stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the transaction, the executive vice president now directly owns 119,184 shares of the company's stock, valued at $3,937,839.36. This trade represents a 18.75 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Scott Dreyer sold 2,255 shares of the company's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $67,650.00. Following the completion of the sale, the executive vice president now owns 124,421 shares in the company, valued at approximately $3,732,630. This trade represents a 1.78 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 109,193 shares of company stock worth $3,243,594 in the last quarter. 3.98% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Invesco Ltd. increased its holdings in shares of Collegium Pharmaceutical by 19.5% during the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock valued at $50,876,000 after acquiring an additional 289,335 shares in the last quarter. Janus Henderson Group PLC increased its stake in Collegium Pharmaceutical by 319.4% during the 4th quarter. Janus Henderson Group PLC now owns 291,388 shares of the specialty pharmaceutical company's stock valued at $8,341,000 after purchasing an additional 221,903 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Collegium Pharmaceutical by 173.6% in the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company's stock worth $10,711,000 after buying an additional 175,892 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Collegium Pharmaceutical in the fourth quarter worth approximately $3,489,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of Collegium Pharmaceutical during the fourth quarter valued at approximately $2,432,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.